Table 1. Demographic and clinical ratings at baseline.
| Variables |
Control |
Remitted |
Statistical comparison between remitted and control groups | ||
|---|---|---|---|---|---|
| Placebo | Vortioxetine | Placebo | Vortioxetine | ||
| N | 24 | 24 | 24 | 24 | |
| Age (years) | 33.8 (9.1) | 34.5 (8.9) | 38.1 (8.8) | 33.1 (9.0) | F<1 |
| Gender (m:f) | 13:11 | 9:15 | 13:11 | 8:16 | Wald χ2=0.03, d.f. =1, P>0.1 |
| Weight (kg) | 72.1 (12.8) | 73.5 (16.7) | 75.1 (16.6) | 71.4 (13.5) | F<1 |
| BMI (kg/m2) | 24.3 (3.4) | 25.8 (4.9) | 25.5 (4.0) | 24.9 (3.6) | F<1 |
| NART IQ score | 116.0 (7.8) | 115.9 (6.6) | 117.6 (6.0) | 118.1 (4.9) | F(1, 89)=2.3, P>0.1 |
| Trait-STAI score | 31.3 (4.8) | 31.3 (3.8) | 40.4 (6.8) | 38.3 (8.1) | F(1, 89)=41.1, P<0.001 |
| State-STAI score | 22.9 (3.5) | 24.6 (5.0) | 28.7 (6.9) | 29.5 (8.4) | F(1, 86)=16.5, P<0.001 |
| PANAS-positive score | 41.2 (5.6) | 37.3 (5.9) | 35.3 (8.1) | 34.3 (6.5) | F(1, 89)=10.8, P=0.001 |
| PANAS-negative score | 11.5 (1.4) | 11.1 (1.5) | 14.4 (3.5) | 13.1 (3.1) | F(1, 89)=21.9, P<0.001 |
| BDI score | 2.8 (1.3) | 3.3 (1.9) | 7.8 (6.7) | 6.9 (7.0) | F(1, 89)=17.1, P<0.001 |
| HAM-D17 baseline score | 0.3 (0.6) | 0.4 (0.7) | 1.6 (2.1) | 1.0 (1.0) | F(1, 89)=14.6, P<0.001 |
| Number of previous MDD episodes | — | — | 2.42 (0.8) | 2.83 (1.2) | |
| Total PDQ score | 12.8 (8.6) | 13.1 (9.0) | 28.2 (11.5) | 28.7 (10.3) | F(1, 89)=59.4, P<0.001 |
Abbreviations: BDI, Beck Depression Inventory; BMI, body mass index; d.f., degrees of freedom; HAM-D17, 17-item Hamilton Depression Rating Scale; MDD, major depressive disorder; MDE, major depressive episode; NART, National Adult Reading Test; PANAS, Positive and Negative Affect Scale; PDQ, Perceived Deficits Questionnaire; STAI, Spielberger State-Trait Anxiety Inventory.
Data are presented as mean (s.d.) and n for gender. Statistics reported are corrected for site and gender.